Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $37.89, but opened at $47.00. Soleno Therapeutics shares last traded at $49.93, with a volume of 806,305 shares traded.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on SLNO shares. Oppenheimer increased their price objective on Soleno Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, January 2nd. Piper Sandler began coverage on shares of Soleno Therapeutics in a report on Monday, February 5th. They set an "overweight" rating and a $93.00 price objective on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Soleno Therapeutics in a research report on Tuesday, January 23rd. They set a "buy" rating and a $63.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $55.60.
Check Out Our Latest Stock Analysis on SLNO
Soleno Therapeutics Stock Performance
The business's 50 day moving average price is $43.07 and its 200-day moving average price is $37.99. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -15.33 and a beta of -1.56.
Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.02). On average, equities research analysts expect that Soleno Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.
Insider Buying and Selling at Soleno Therapeutics
In other Soleno Therapeutics news, CEO Bhatnagar Anish sold 18,980 shares of the business's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $41.34, for a total value of $784,633.20. Following the transaction, the chief executive officer now directly owns 152,790 shares in the company, valued at $6,316,338.60. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Soleno Therapeutics news, insider Kristen Yen sold 2,218 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $41.34, for a total value of $91,692.12. Following the completion of the sale, the insider now owns 23,422 shares in the company, valued at approximately $968,265.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bhatnagar Anish sold 18,980 shares of the business's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $41.34, for a total transaction of $784,633.20. Following the completion of the transaction, the chief executive officer now owns 152,790 shares of the company's stock, valued at approximately $6,316,338.60. The disclosure for this sale can be found here. Insiders have sold 26,373 shares of company stock worth $1,090,260 over the last three months. Company insiders own 28.80% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of SLNO. Vivo Capital LLC raised its position in shares of Soleno Therapeutics by 162.8% in the 4th quarter. Vivo Capital LLC now owns 8,418,093 shares of the company's stock valued at $338,828,000 after acquiring an additional 5,215,000 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Soleno Therapeutics in the third quarter valued at $39,160,000. Vestal Point Capital LP bought a new stake in shares of Soleno Therapeutics in the 4th quarter valued at about $52,325,000. RA Capital Management L.P. acquired a new stake in shares of Soleno Therapeutics in the third quarter valued at approximately $36,563,000. Finally, Carlyle Group Inc. grew its stake in Soleno Therapeutics by 90.9% in the 3rd quarter. Carlyle Group Inc. now owns 2,293,562 shares of the company's stock valued at $67,431,000 after buying an additional 1,092,056 shares during the last quarter. 97.42% of the stock is currently owned by institutional investors.
About Soleno Therapeutics
(
Get Free Report)
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Featured Articles
Before you consider Soleno Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.
While Soleno Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
